Medacta Group (MOVE.SW) Osake Kurssi
Medacta Group Kurssi
Viimeisten 9 vuoden aikana Medacta Groupn liikevaihto kasvoi 13,5 % vuodessa ja ylsi 681,46 M EUR:een. Osakekohtainen tulos on kasvanut 10,4 % vuodessa viimeisten 9 vuoden aikana. Medacta Groupn nettomarginaali 14,1 % on pääosin vakaa verrattuna 14,4 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 0,28 %. Jakosuhde on noin 8 % tuloksesta. Osinko on kasvanut 8,8 % vuodessa viimeisten 3 vuoden aikana. Medacta Groupn 12 kuukauden konsensustavoitehinta on 176,14 EUR, noin yli kurssia 41,4 %. 11 analyytikosta 9 suosittaa ostoa — kokonaiskonsensus on Osta.
Medacta Group osakekurssi
Medacta Group liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Medacta Group -osakkeesta
Medacta Group SA operates under a medical technology business model. As a leading manufacturer in the orthopedic industry, Medacta specializes in designing, developing, and distributing innovative surgical solutions. The company is primarily focused on providing integrated solutions for joint replacement, spine surgery, and sports medicine. Medacta aims to improve patient outcomes by offering a comprehensive range of products, including implants, instruments, and computer-assisted technologies. With a commitment to research and development, Medacta continuously pushes the boundaries of medical technology, enabling healthcare professionals to deliver advanced and personalized care to patients worldwide.
Medacta Group SA is primarily active in the medical industry. As an innovative medical device company, Medacta specializes in developing and manufacturing orthopedic implants and surgical instruments. With a focus on personalized solutions, the company offers products for various medical procedures, including joint replacement, spine surgery, and sports medicine. Leveraging advanced technologies and research expertise, Medacta aims to improve patient outcomes and enhance surgical techniques. With its unwavering commitment to innovation and quality, Medacta Group SA has established itself as a prominent player in the medical field.
The main competitors of Medacta Group SA in the market are other companies in the orthopedic medical device industry, such as Zimmer Biomet Holdings Inc., Stryker Corporation, and Johnson & Johnson. These companies also specialize in producing and marketing orthopedic implants and surgical instruments. Medacta Group SA faces competition from these established players, but it differentiates itself through its innovative product offerings, strong focus on customer satisfaction, and dedication to continuous research and development. Its commitment to providing high-quality orthopedic solutions positions Medacta Group SA as a leading player in the market.
Medacta Group SA is a leading Swiss medical device company specializing in orthopedic products and services. Founded in 1999 by Dr. Alberto Siccardi, Medacta has grown to become a trusted player in the global healthcare industry. The company focuses on developing innovative solutions for joint replacement, spine surgery, and sports medicine. With a strong commitment to research and development, Medacta has revolutionized surgical approaches and attained international recognition. Medacta's dedication to providing surgeons with state-of-the-art tools and patients with improved outcomes has led to its global success. As a reputable supplier in the medical field, Medacta Group SA continues to strive for excellence in its products and services for the benefit of patients worldwide.
Medacta Group SA has achieved several significant milestones. Firstly, the company has successfully expanded its global presence, operating in over 50 countries worldwide. Additionally, Medacta Group SA has demonstrated continuous innovation in the field of medical devices and orthopedic solutions. The company has received numerous accolades for its cutting-edge technologies and advanced research initiatives. Medacta Group SA has also shown resilience during challenging times, maintaining steady growth in revenue and market share. Overall, the company's commitment to excellence and dedication to improving patient outcomes have positioned Medacta Group SA as a trusted leader in the healthcare industry.
Medacta Group SA is primarily present in Europe, the United States, and Asia. The company has a strong presence in countries such as Switzerland, Italy, Germany, France, Spain, the United Kingdom, and the Netherlands. Additionally, Medacta Group SA has established a significant footprint in North America, with a focus on the United States. The company's presence in Asia includes countries like Japan, China, South Korea, Malaysia, and Singapore. Medacta Group SA's global presence enables it to provide its innovative medical solutions and orthopedic products to a wide range of healthcare professionals and patients around the world.
Medacta Group SA represents values of innovation, excellence, and patient-centricity in the healthcare industry. As a leading medical device company, Medacta focuses on developing and providing cutting-edge surgical solutions to enhance patient outcomes and improve the quality of life. The company's corporate philosophy revolves around collaboration, integrity, and a strong commitment to continuous improvement. Medacta strives to establish long-term partnerships with surgical teams, ensuring the highest standards of safety and efficiency. By consistently prioritizing patient well-being and leveraging its technological expertise, Medacta Group SA remains at the forefront of advancing medical advancements and delivering top-notch surgical solutions globally.
Analyytikot asettavat tällä hetkellä Medacta Group-osakkeelle keskimääräisen tavoitehinnan 181,18 EUR (mediaani: 176,14 EUR), mikä merkitsee +45,5 % viimeisimpään hintaan verrattuna. Konsensus perustuu 11 analyytikkoarvioon.
11 analyytikkoa arvioi tällä hetkellä Medacta Group-osaketta: 9 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Medacta Group-yhtiöltä 753,90 M EUR liikevaihtoa ja 4,76 EUR osakekohtaista tulosta.
Medacta Group-osake (MOVE.SW) on listattuna 7 pörssissä, muun muassa: London (0A05.L), SIX (Zürich) (MOVE.SW), Frankfurt (6MD.F), München (6MD.MU), Düsseldorf (6MD.DU).
Medacta Group SA is a leading medical technology company specializing in the development, production, and marketing of innovative surgical solutions. The company operates globally and offers products and services in various business areas including orthopedics, spine, robotics, and traumatology. They also have expertise in digital health, offering solutions in telemedicine, risk management, and surgical planning. Their business model focuses on continuous improvement to provide high-quality products and collaborations with medical professionals to meet their needs. Through research and development, they aim to bring innovative technologies to the healthcare industry. Overall, Medacta Group SA offers a wide range of products and services tailored to the needs of healthcare professionals and patients, establishing themselves as a leading company in the medical technology industry.
odotettu liikevaihto Medacta Group on 753,90 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Medacta Group on 95,86 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Medacta Group:n hinta-voitto-suhde (P/E) on tällä hetkellä 26,15. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Medacta Group-osakkeen arvostusta.
Medacta Group:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,32. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Medacta Group-osakkeen arvostuskennuslukuna.
Medacta Group:n Eulpool-laatuscore on 6/10.
Medacta Group:n ISIN on CH0468525222. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Medacta Group:n WKN on A2PFTD. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Medacta Group:n ticker on MOVE.SW. Tämä pörssinoteeraus käytetään Medacta Group-osakkeiden kauppaan pörssissä.
Medacta Group osake
Medacta Group vertaisryhmä
Medacta Group Ticker
Medacta Group FIGI
Kaikki tunnusluvut ja syvällinen analyysi Medacta Group:sta
Meidän osakeanalyysimme Medacta Group-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Medacta Group:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: